France confirmed AstraZeneca COVID-19 vaccine can cause blood clots

France confirmed AstraZeneca COVID-19 vaccine can cause blood clots.  French Pharmaceutical Safety Agency confirms: AstraZeneca vaccine can cause rare blood clots.

France has resumed vaccination against AstraZeneca’s COVID-19 vaccine since the 19th. The preliminary investigation results released by the European Medicines Agency on the 18th showed that the COVID-19 vaccine jointly developed by AstraZeneca and Oxford University “benefits outweigh the risks”, but it is not ruled out that it is related to a very small number of thrombosis cases.

Previously, many European countries announced the suspension of the use of AstraZeneca vaccine due to concerns about the possible risk of blood clots after vaccination. The picture shows a pharmacist vaccinating an old man with AstraZeneca’s COVID-19 vaccine in Tourcoing, a city in northern France, on March 19th. Published by Xinhua News Agency (Photo by Sebastian Kurgi)

The French Agency for the Safety of Medicines (ANSM) confirmed on the 26th that the AstraZeneca vaccine has a “rare” risk that can cause atypical thrombosis. There have been many cases of vaccinated patients in France recently with thrombosis, especially during the period from March 12th to 18th, which caused 2 deaths.

According to the latest data from ANSM monitoring, 9 people in France experienced venous thrombosis after being vaccinated with AstraZeneca from the 12th to the 18th. The location is atypical, mainly in the cerebral veins and digestive tract. This may be related to the patient’s thrombocytopenia or coagulopathy. related. Two of the nine people died, including a medical student from the University of Nantes, who had an internship at the school’s affiliated hospital before his death. The French health authorities are launching an in-depth clinical investigation of the case.

According to ANSM, these rare cases of atypical thrombosis have similar clinical pictures and onset time. The median time to thrombosis after vaccination is 8.5 days. The patient has no specific medical history. Among them, 7 patients were under 55 years old and 2 were over 55 years old.

Due to concerns about the risk of thrombosis caused by the AstraZeneca vaccine, many European countries have suspended vaccination of the vaccine since March 15. The preliminary investigation results released by the European Medicines Agency on the 18th showed that the AstraZeneca vaccine is safe and effective, and the benefits outweigh the risk of adverse reactions; the vaccine will not increase the overall risk of blood clots among the vaccinators; there is no evidence that there have been cases of thrombosis and specific batches. Related to the AstraZeneca vaccine produced at a second or specific location; however, the association between these thrombosis cases and the vaccine cannot be clearly ruled out.

The European Medicines Agency recommended to continue vaccination, and France lifted the ban on vaccination on the 19th, but the French High Health Administration (HAS) recommended that the vaccine be used only for people 55 years and older, because the previous cases of thrombosis were concentrated in people under 55. Previously, French medical staff under the age of 50 without complications could only receive the AstraZeneca vaccine.

As of March 18, among the 1.4 million doses of AstraZeneca vaccine injected in France, the Pharmacovigilance Center has observed about 5,700 adverse reactions, most of which are high-intensity flu-like syndromes, including fever, headaches and muscles. Sore.

At present, AstraZeneca vaccine has become the largest single-day vaccination in France. ANSM emphasized that the benefits of AstraZeneca vaccination still outweigh the risks of adverse reactions.

(source:internet, reference only)

Disclaimer of medicaltrend.org